Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
- 1 January 2018
- journal article
- research article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 155 (1) , 382-392.e1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- PD-L1 Expression in Lung CancerJournal of Thoracic Oncology, 2016
- Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2016
- Scientific Advances in Lung Cancer 2015Journal of Thoracic Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)Surgery Today, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012